A phase I study of combination therapy with immunotoxins IgG-HD37- deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1302-1313

  Messmann, Richard A ^a,b   Vitetta, Ellen S ^c   Headlee, Donna ^b   Senderowicz, Adrian M ^a   Figg, William D ^b   Schindler, John ^c   Michiel, Dennis F ^d   Creekmore, Steven ^b   Steinberg, Seth M ^b   Kohler, David ^b   Jaffe, Elaine S ^b   Stetler Stevenson, Maryalice ^b   Chen, Huachun ^b   Ghetie, Victor ^c   Sausville, Edward A ^a  

^a Vascular Medicine Branch   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD22 ANTIGEN; COMBOTOX; IMMUNOGLOBULIN G; IMMUNOTOXIN; MONOCLONAL ANTIBODY; RICIN A; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CROSS LINKING; DRUG EFFECT; FEMALE; GLYCOSYLATION; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; AREA UNDER CURVE; CAPILLARY PERMEABILITY; CELL ADHESION MOLECULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; FEVER; HUMANS; IMMUNOTOXINS; INFUSIONS, INTRAVENOUS; LECTINS; LYMPHOMA, B-CELL; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; RICIN; TREATMENT OUTCOME;

EID: 0034092593     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer (Phila.), 49: 2112, 1982.
2. Armitage, J. O., Fyfe, M. A., and Lewis, J. Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J. Clin. Oncol., 2: 898, 1984.
3. DeVita, V. T., Hellman, S., and Rosenberg, S. A. Cancer: Principles and Practice of Oncology, 2nd Ed. Philadelphia: Lippincott, 1985.
4. Vitetta, E. S., Fulton, R. J., May, R. D., Till, M., and Uhr, J. W. Redesigning nature's poisons to create anti-tumor reagents. Science (Washington DC), 238: 1098, 1987.
5. DeVita, V. T., Hellman, S., and Rosenberg, S. A. Biologic therapy of cancer. Philadelphia: Lippincott, 1991.
6. Pastan, I., and FitzGerald, D. Pseudomonas exotoxin: chimeric toxins. J. Biol. Chem., 264: 15157, 1989.
7. Ghetie, M. A., Tucker, K., Richardson, J., Uhr, J. W., and Vitetta, E. S. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood, 80: 2315, 1992.
8. Sausville, E. A., Headlee, D., Stetler-Stevenson, M., Jaffe, E. S., Solomon, D., Figg, W. D., Herdt, J., Kopp, W. C., Rager, H., Steinberg, S. M., Ghetie, V., Schindler, J., Uhr, J., Wittes, R., and Vitetta, E. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a Phase I study. Blood, 85: 3457, 1995.
9. Stone, M. J., Sausville, E. A., Fay, J. W., Headlee, D., Collins, R. H., Figg, W. D., Stetler-Stevenson. M., Jain, V., Jaffe, E. S., Solomon, D., Lush, R. M., Senderowicz, A., Ghetie, V., Schindler, J., Uhr, J. W., and Vitetta, E. S. A Phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin. IgG-HD37-dgA, in patients with B-cell lymphoma. Blood, 88: 1188, 1996.
10. Pezzutto, A., Dorken, B., Rabinovitch, P. S., Ledbetter, J. A., Moldenhauer, G., and Clark. E. A. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J. Immunol., 138: 2793, 1987.
11. Ghetie, M. A., Picker, L. J., Richardson, J. A., Tucker, K., Uhr, J. W., and Vitetta, E. S. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood, 83: 1329, 1994.
12. Kuchnio, M., Sausville, E. A., Jaffe, E. S., Greiner, T., Foss, F. M., McClanahan, J., Fukushima, P., and Stetler-Stevenson, M. A. Flow cytometric detection of neoplastic T cells in patients with mycosis fungoides based on levels of T-cell receptor expression. Am. J. Clin. Pathol., 102: 856, 1994.
13. Fukushima, P., Nguyen, P., O'Grady, P., and Stetler-Stevenson, M. Flow cytometric analysis of kappa and lambda light chain expression in evaluation of specimens for B-cell neoplasia. Cytometry, 26: 243, 1996.
14. Fulton, R. J., Blakey, D. C., Knowles, P. P., Uhr, J. W., Thorpe, P. E., and Vitetta, E. S. Purification of ricin A1, A2, and B chains and characterization of their toxicity. J. Biol. Chem., 261: 5314, 1986.
15. Ghetie, V., Ghetie, M. A., Uhr, J. W., and Vitetta, E. S. Large scale preparation of immunotoxins constructed with the Fab' fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain. J. Immunol. Methods, 112: 267, 1988.
16. Knowles, P. P., and Thorpe, P. E. Purification of immunotoxins containing ricin A-chain and abrin A-chain using blue Sepharose CL-6B. Anal Biochem, 160: 440, 1987.
17. Richardson, A. P., Mountford, P. J., Baird, A. C., Heyderman, E., Richardson, T. C., and Coakley, A. J. An improved iodogen method of labelling antibodies with 123I. Nucl. Med. Commun., 7: 355, 1986.
18. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207, 1981.
19. Wittes, R. E. Manual of Oncologic Therapeutics, 1991/1992. Philadelphia: Lippincott, 1991.
20. Vitetta, E. S., Stone, M., Amlot, P., Fay, J., May, R., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, D., Ghetie, V., Uhr, J., and Thorpe, P. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res., 51: 4052, 1991.
21. Sausville, E. A., and Vitetta, E. S. Clinical studies with deglycosylated Ricin A-chain immunotoxins. In: M. Grossbard (ed.), Monoclonal Antibody-based Therapy of Cancer, Ed. 4, p. 81. New York: Marcel Dekker, Inc. 1997.
22. Lindstrom, A. L., Erlandsen, S. L., Kersey, J. H., and Pennell, C. A. An in vitro model for toxin-mediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell and monolayers. Blood, 90: 2323, 1997.
23. Amlot, P. L., Stone, M. J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., Ghetie, V., Ramilo, O., Thorpe, P., Uhr, J., Vitetta, E. A Phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82: 2624, 1993.
24. Duvic, M., Cather, J., Maize, J., and Frankel, A. E. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am. J. Hematol., 58: 87, 1998.
25. Engert, A., Diehl, V., Schnell, R., Radszuhn, A., Hatwig, M. T., Drillich, S., Schon, G., Bohlen, H., Tesch, H., Hansmann, M. L., Barth, S., Schindler, J., Ghetie, V., Uhr, J., and Vitetta, E. A Phase I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood, 89: 403, 1997.
26. Frankel, A. E., Laver, J. H., Willingham, M. C., Burns, L. J., Kersey, J. H., and Vallera, D. A. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk. Lymphoma, 26: 287, 1997.
27. Ghetie, M. A., May, R. D., Till, M., Uhr, J. W., Ghetie, V., Knowles, P. P., Relf, M., Brown, A., Wallace, P. M., Janossy, G., Amlot, P., Vitetta, E., and Thorpe, P. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy (Published erratum in Cancer Res., 48: 4716, 1988]. Cancer Res., 48: 2610, 1988.
28. Kuan, C. T., Pai, L. H., and Pastan, I. Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clin. Cancer Res., 1: 1589, 1995.
29. LeMaistre, C. F., Saleh, M. N., Kuzel, T. M., Foss, F., Platanias, L. C., Schwartz, G., Ratain, M., Rook, A., Freytes, C. O., Craig, F., Reuben, J., and Nichols, J. C. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood, 91: 399, 1998.
30. Meneghetti, C. M., and LeMaistre, C. F. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2). Targeted Diagn. Then, 7: 395, 1992.
31. Soler-Rodriguez, A. M., Ghetie, M. A., Oppenheimer-Marks, N., Uhr, J. W., and Vitetta, E. S. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp. Cell Res., 206: 227, 1993.
32. Baluna, R., Rizo, J., Gordon, B. E., Ghetie, V., and Vitetta, E. S. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl. Acad. Sci. USA, 96: 3957, 1999.
33. Taylor, C. M., Williams, J. M., Lote, C. J., Howie, A. J., Thewles, A., Wood, J. A., Milford, D. V., Raafat, F., Chant, I., and Rose, P. E. A laboratory model of toxin-induced hemolytic uremic syndrome. Kidney Int., 55: 1367, 1999.
34. Williams, D. P., Parker, K., Bacha, P., Bishai, W., Borowski, M., Genbauffe, F., Strom, T. B., and Murphy, J. R. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng., 1: 493, 1987.
35. LeMaistre, C. F., Meneghetti, C., Rosenblum, M., Reuben, J., Parker, K., Shaw, J., Deisseroth, A., Woodworm, T., and Parkinson, D. R. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood, 79: 2547, 1992.
36. LeMaistre, C. F., Craig, F. E., Meneghetti, C., McMullin, B., Parker, K., Reuben, J., Boldt, D. H., Rosenblum, M., and Woodworth, T. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res., 53: 3930, 1993.
37. Bertomeu, M. C., Gallo, S., Lauri, D., Levine, M. N., Orr, F. W., and Buchanan, M. R. Chemotherapy enhances endothelial cell reactivity to platelets. Clin. Exp. Metastasis, 8: 511, 1990.
38. Baker, D. G., and Krochak, R. J. The response of the microvascular system to radiation: a review. Cancer Invest., 7: 287, 1989.
39. Ghetie, M. A., Podar, E. M., Ilgen, A., Gordon, B. E., Uhr, J. W., and Vitetta, E. S. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA, 94: 7509, 1997.
40. Ghetie, V., Thorpe, P., Ghetie, M. A., Knowles, P., Uhr, J. W., and Vitetta, E. S. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond. J. Immunol. Methods, 142: 223, 1991.
41. Ghetie, M. A., Uhr, J. W., and Vitetta, E. S. Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins. Cancer Res., 51: 1482, 1991.
42. Senderowicz, A. M., Vitetta, E., Headlee, D., Ghetie, V., Uhr, J. W., Figg, W. D., Lush, R. M., Stetler-Stevenson, M., Kershaw, G., Kingma, D. W., Jaffe, E. S., and Sausville, E. A. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann. Intern. Med., 126: 882, 1997.